Skip to main content
. 2020 Mar 27;10:5653. doi: 10.1038/s41598-020-62530-w

Table 2.

Comparison of Functional Activities at Opioid Receptors of N-Methylmorphinans 1–4 and Their N-Phenethyl Analogues 1a4a.

Compound µORa δORa κORa
EC50 (nM) % stim. EC50 (nM) % stim. EC50 (nM) % stim.
Morphine (1) 34.4 ± 5.1b 89 ± 17b 668 ± 65b 109 ± 14b 710 ± 23b 76 ± 2b
1a 10.3 ± 0.9b* 113 ± 8b 712 ± 86b 138 ± 17b 1049 ± 29b 19 ± 2b***
Oxymorphone (2) 7.80 ± 1.61b 92 ± 5b 259 ± 33b 87 ± 40b 463 ± 116b 48 ± 11b
2a 2.67 ± 1.06b* 97 ± 3b 131 ± 60b 101 ± 9b 225 ± 74b 7.5 ± 0.01b*
14-OMO (3) 1.21 ± 0.48 95 ± 5 38.5 ± 6.9 102 ± 4 135 ± 29 65.9 ± 6.5
3a 1.26 ± 0.63 98 ± 10 9.34 ± 0.60* 107 ± 5 144 ± 9 35.4 ± 7.5*
14-MM (4) 2.66 ± 0.58 99 ± 5 36.8 ± 12.4 100 ± 9 181 ± 9 68.9 ± 9.2
4a 1.86 ± 0.84 102 ± 13 9.54 ± 2.33* 103 ± 2 334 ± 114 51.3 ± 10.4

aDetermined in [35S]GTPγS binding assays using membranes from CHO cells stably expressing the human opioid receptors. Percentage stimulation (% stim.) relative to the agonist DAMGO (µOR), DPDPE (δOR) or U69,593 (κOR). Values represent the mean ± SEM (n = 3–4). bData from ref. 13. *P < 0.05, **P < 0.01 and ***P < 0.001 for N-methylmorphinans vs. respective N-phenethyl analogues (unpaired t-test).